Grimes & Company, Inc. Cassava Sciences Inc Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$8.56 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$6.71 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$3.09 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.68 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.54 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $107M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...